Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
32 pending office actions • 9 art units • 24 examiners • 0 of 32 (0%) have an AI response strategy ready • 29 patents granted in the last 365 days
INCYTE Corporation manages a portfolio with 31 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 24 distinct examiners, indicating that several examiners are handling multiple cases for the company. The prosecution activity is spread across 8 distinct art units, reflecting the technical range of the pending applications.
CHAO, ALLEN is the busiest examiner for the portfolio, currently overseeing 4 pending office actions. This concentration under a single examiner makes CHAO, ALLEN a central figure in the company's current prosecution strategy. With 31 pending office actions in total, the legal team must manage examiner communications across 8 distinct art units. The involvement of 24 distinct examiners requires a coordinated approach to ensure consistency across the various matters in the Biotechnology & Pharmaceuticals sector.
Based on the USPTO statutory response window for each pending office action. 7 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 7 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 5 (16%) |
| §102 only | 1 (3%) |
| §112 only | 9 (28%) |
| Double-patenting only | 5 (16%) |
| Double-patenting + other | 5 (16%) |
| Multi-statute (no §101) | 7 (22%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHAO, ALLEN | 4 | 55.6% | +0.0% |
| RAHMANI, NILOOFAR | 2 | 77.5% | -2.9% |
| AULAKH, CHARANJIT | 2 | 80.6% | -14.5% |
| SHIAO, REI TSANG | 2 | 79.8% | -33.6% |
| GAO, ASHLEY HARTMAN | 2 | 56.7% | +38.2% |
| DAHLE, CHUN WU | 2 | 50.2% | +51.2% |
| WARD, PAUL V | 1 | 83.2% | -12.2% |
| NESTOR, DONNA MICHELLE | 1 | 56.6% | +44.2% |
| RZECZYCKI, PHILLIP MATTHEW | 1 | 64.8% | +37.0% |
| SHTERENGARTS, SAMANTHA L | 1 | 79.5% | +8.0% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18960485 | SALTS OF TAM INHIBITORS | WARD, PAUL V | — |
| 18678931 | TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | AULAKH, CHARANJIT | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18056907 | MULTISPECIFIC BINDING MOIETIES COMPRISING PD-1 AND TGF-BRII BINDING DOMAINS | CUNNINGCHEN, KATHLEEN MARY | 15d |
| 18980424 | BICYCLOOCTANE KRAS INHIBITORS | RAHMANI, NILOOFAR | — |
| 18871262 | BICYCLIC AMINE CDK12 INHIBITORS | AULAKH, CHARANJIT | — |
| 18581959 | COMBINATIONS AND USES THEREOF | DAHLE, CHUN WU | — |
| 18411350 | COMBINATIONS AND USES THEREOF | DAHLE, CHUN WU | — |
| 18245019 | TOPICAL TREATMENT OF VITILIGO | SOROUSH, LAYLA | — |
| 17541627 | ANTI-CD19 COMBINATION THERAPY | MIDDLETON, DANAYA L | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18625703 | NOVEL PD-1 BINDING DOMAINS | GAO, ASHLEY HARTMAN | 15d |
| 18953578 | IMIDAZ0[1,2-A]PYRIMIDINE-5(1 H)-ONES AS WRN INHIBITORS | NESTOR, DONNA MICHELLE | — |
| 18807221 | BICYCLIC HETEROCYCLES AS MRGPRX2 ANTAGONISTS | RZECZYCKI, PHILLIP MATTHEW | — |
| 18625756 | NOVEL PD-1 BINDING DOMAINS | GAO, ASHLEY HARTMAN | — |
| 18581959 | COMBINATIONS AND USES THEREOF | DAHLE, CHUN WU | — |
| 18411350 | COMBINATIONS AND USES THEREOF | DAHLE, CHUN WU | — |
| Art Unit | Apps |
|---|---|
| 1622 | 6 |
| 1625 | 2 |
| 1678 | 2 |
| 1646 | 2 |
| 1629 | 2 |
| 1621 | 1 |
| 1624 | 1 |
| 1674 | 1 |
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18980424 | BICYCLOOCTANE KRAS INHIBITORS | RAHMANI, NILOOFAR | — | §102§112 | Non-Final OA | — | Pending | Dec 13, 2024 |
| 18871262 | BICYCLIC AMINE CDK12 INHIBITORS | AULAKH, CHARANJIT | — | §103§112 | Non-Final OA | — | Pending | Dec 03, 2024 |
| 18960485 | SALTS OF TAM INHIBITORS | WARD, PAUL V | — | DP | Non-Final OA | — | Pending | Nov 26, 2024 |
| 18953578 | IMIDAZ0[1,2-A]PYRIMIDINE-5(1 H)-ONES AS WRN INHIBITORS | NESTOR, DONNA MICHELLE | — | DP | Non-Final OA | — | Pending | Nov 20, 2024 |
| 18827269 | Kinase Inhibitors | SHIAO, REI TSANG | — | DP | Non-Final OA | — | Pending | Sep 06, 2024 |
| 18821138 | BICYCLIC COMPOUNDS AS INHIBITORS OF WRN | SHIAO, REI TSANG | — | §102§103DP | Non-Final OA | — | Pending | Aug 30, 2024 |
| 18807221 | BICYCLIC HETEROCYCLES AS MRGPRX2 ANTAGONISTS | RZECZYCKI, PHILLIP MATTHEW | — | §112 | Non-Final OA | — | Pending | Aug 16, 2024 |
| 18777124 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | SHTERENGARTS, SAMANTHA L | — | DP | Non-Final OA | — | Pending | Jul 18, 2024 |
| 18736628 | BICYCLIC AMINES AS CDK2 INHIBITORS | HEITMEIER, KENDALL NICOLE | — | §103§112DP | Non-Final OA | — | Pending | Jun 07, 2024 |
| 18678931 | TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | AULAKH, CHARANJIT | 1621 | §112DP | Final Rejection | — | Pending | May 30, 2024 |
| 18675743 | PYRAZOLOQUINOLINE KRAS INHIBITORS | RAHMANI, NILOOFAR | — | §102 | Non-Final OA | — | Pending | May 28, 2024 |
| 18671477 | IMIDAZOPYRIDAZINE AND IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF | CHANDRAKUMAR, NIZAL S | 1625 | §103Other | Non-Final OA | — | Pending | May 22, 2024 |
| 18640382 | USE OF JAK1 INHIBITORS FOR THE TREATMENT OF CUTANEOUS LUPUS ERYTHEMATOSUS AND LICHEN PLANUS (LP) | HUI, SAN MING R | — | §103 | Non-Final OA | — | Pending | Apr 19, 2024 |
| 18638034 | CYCLIC UREA KRAS INHIBITORS | KIFLE, BRUCK | 1624 | §112 | Final Rejection | — | Pending | Apr 17, 2024 |
| 18625703 | NOVEL PD-1 BINDING DOMAINS | GAO, ASHLEY HARTMAN | 1678 | DP | Non-Final OA | 15d | Pending | Apr 03, 2024 |
| 18625756 | NOVEL PD-1 BINDING DOMAINS | GAO, ASHLEY HARTMAN | 1678 | §112 | Non-Final OA | — | Pending | Apr 03, 2024 |
| 18602434 | Bicyclic Ureas As Kinase Inhibitors | CHAO, ALLEN | 1622 | §112 | Non-Final OA | — | Pending | Mar 12, 2024 |
| 18598812 | JAK1 PATHWAY INHIBITORS FOR THE TREATMENT OF VITILIGO | VALENROD, YEVGENY | — | §103DP | Non-Final OA | — | Pending | Mar 07, 2024 |
| 18584553 | Heterocyclic Compounds As Kinase Inhibitors | CHAO, ALLEN | 1622 | §112 | Non-Final OA | — | Pending | Feb 22, 2024 |
| 18581959 | COMBINATIONS AND USES THEREOF | DAHLE, CHUN WU | — | §103§112 | Non-Final OA | — | Pending | Feb 20, 2024 |
| 18411350 | COMBINATIONS AND USES THEREOF | DAHLE, CHUN WU | — | §103§112 | Non-Final OA | — | Pending | Jan 12, 2024 |
| 18512625 | Heteroaryl Fluoroalkenes As DGK Inhibitors | CHAO, ALLEN | 1622 | §112 | Non-Final OA | — | Pending | Nov 17, 2023 |
| 18512514 | Heteroaryl Fluoroalkenes As DGK Inhibitors | CHAO, ALLEN | 1622 | §112 | Non-Final OA | — | Pending | Nov 17, 2023 |
| 18373648 | ANTI-PD-1/LAG-3 BISPECIFIC ANTIBODIES AND USES THEREOF | REDDIG, PETER J | 1646 | §103Other | Non-Final OA | 27d | Pending | Sep 27, 2023 |
| 18232970 | TRICYCLIC TRIAZOLO COMPOUNDS AS DGK INHIBITORS | REDWOOD, CHRISTOPHER EVAN | 1629 | §103 | Final Rejection | 25d overdue | Pending | Aug 11, 2023 |
| 18349606 | FUSED TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS G12V MUTANTS | DEKARSKE, MADELINE MCGUIRE | 1622 | §103Other | Final Rejection | 46d | Pending | Jul 10, 2023 |
| 18192313 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS | BELL, SARA ELIZABETH | 1625 | §112Other | Non-Final OA | 6d | Pending | Mar 29, 2023 |
| 18245019 | TOPICAL TREATMENT OF VITILIGO | SOROUSH, LAYLA | 1622 | §102§103§112 | Non-Final OA | — | Pending | Mar 13, 2023 |
| 18179838 | SOLID FORMS, SALTS, AND PROCESSES OF PREPARATION OF A CDK2 INHIBITOR | TOWNSLEY, SARA ELIZABETH | 1629 | §112 | Final Rejection | 28d overdue | Pending | Mar 07, 2023 |
| 18056907 | MULTISPECIFIC BINDING MOIETIES COMPRISING PD-1 AND TGF-BRII BINDING DOMAINS | CUNNINGCHEN, KATHLEEN MARY | 1646 | §102§103§112Other | Final Rejection | 15d | Pending | Nov 18, 2022 |
| 17541627 | ANTI-CD19 COMBINATION THERAPY | MIDDLETON, DANAYA L | 1674 | §103§112Other | Non-Final OA | — | Pending | Dec 03, 2021 |
| 16791561 | CYCLIN-DEPENDENT KINASE 2 BIOMARKERS AND USES THEREOF | KATAKAM, SUDHAKAR | 1658 | §103DP | Final Rejection | — | Pending | Feb 14, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial